ESLICARBAZEPINE ACETATE | A211199 | ALKEM LABORATORIES LTD
| Case | Court | Filed | Status | Judge |
|---|---|---|---|---|
BIAL - PORTELA & CA S.A. et al v. Alkem Laboratories Limited 6 patentsANDA 211199Eslicarbazepine Acetate | D. Del. | 2018-02-22 | Terminated 2022-10-24 | — |
Source: PACER. NOS 835 (Patent - Abbreviated New Drug Application).
Highest NADAC/Unit
$2.95
per ea
Lowest NADAC/Unit
$2.06
per ea
Brand NDCs
0
Generic NDCs
4
| NDC Description | NADAC/Unit | Unit | Type | Generic NADAC | Effective |
|---|---|---|---|---|---|
| 67877058760ESLICARBAZEPINE 600 MG TABLET | $2.95 | EA | Generic | — | 2026-06-17 |
| 67877058630ESLICARBAZEPINE 400 MG TABLET | $2.93 | EA | Generic | — | 2026-06-17 |
| 67877058830ESLICARBAZEPINE 800 MG TABLET | $2.65 | EA | Generic | — | 2026-06-17 |
| 67877058530ESLICARBAZEPINE 200 MG TABLET | $2.06 | EA | Generic | — | 2026-06-17 |
Source: NADAC (data.medicaid.gov). Prices reflect national average acquisition costs for retail community pharmacies.
No patent or exclusivity listings for this strength.